Seroprevalence of parvovirus B19 in the German population

Epidemiology and Infection

Volumn 136, Issue 11, 2008, Pages 1564-1575

  Rohrer C ^a   Gartner B ^b   Sauerbrei, A ^c   Bohm S ^a   Hottentrager B ^a   Raab, U ^a   Thierfelder, W ^d   Wutzler, P ^c   Modrow, Susanne ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c Institut für Virologie und Antivirale Therapie   (Germany)

^d ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CHILD; CITY; CONTROLLED STUDY; ERYTHEMA INFECTIOSUM; FEMALE; GERMANY; GROUPS BY AGE; HEALTH SURVEY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL HAZARD; PARVOVIRUS; POPULATION RESEARCH; PREGNANCY; RURAL AREA; SEROPREVALENCE; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANIMALS; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; URBAN POPULATION;

EID: 54049114703     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268807009958     Document Type: Article

References (34)

1. Heegaard ED, Brown KE. Human parvovirus B19. Clinical Microbiology Reviews 2002; 15: 485-505.
2. Kerr JR, Modrow S. Human and primate parvovirus infections and associated disease. In: Berns K, et al., eds. Parvoviruses. London, UK: Arnold Publishers, Hodder, 2006, pp. 385-416.
3. Miller E, et al. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. British Journal of Obstetrics and Gynaecology 1998; 105: 174-178.
4. Yaegashi N, et al. Serologic study of human parvovirus B19 infection in pregnancy in Japan. Journal of Infection 1999; 38 30-35.
5. Yaegashi N, et al. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. Journal of Infection 1998; 37: 28-35.
6. Gilbert GL. Parvovirus B19 infection and its significance in pregnancy. Communicable Diseases Intelligence 2000; 24 (Suppl.): 69-71.
7. Enders M, et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: Prospective evaluation of 1018 cases. Prenatal Diagnosis 2004; 24: 513-518.
8. Chorba T, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). Journal of Infectious Diseases 1986; 154: 383-393.
9. Enders M, Weidner A, Enders G. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany. Epidemiology and Infection 2006; 26 1-7.
10. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. Journal of Medical Microbiology 1988; 25: 151-153.
11. Kelly HA, et al. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiology and Infection 2000; 124: 449-457.
12. Tsujimura M, et al. Human parvovirus B19 infection in blood donors. Vox Sanguinis 1995; 69: 206-212.
13. Vyse AJ, et al. The burden of parvovirus B19 infection in women of childbearing age in England and Wales. Epidemiology and Infection 2007; 12: 1-9.
14. Pfrepper KI, Enders M, Motz M. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection. Journal of Veterinary Medicine. Series B: Infectious Diseases and Veterinary Public Health 2005; 52: 362-365.
15. Eis-Hübinger AM, et al. The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zentralblatt für Bakteriologie 1996; 284: 232-240.
16. Thefeld W, Stolzenberg H, Bellach BM. The Federal Health Survey: response, composition of participants and non-responder analysis. Gesundheitswesen 1999; 61 (Suppl 2): 57-61.
17. Ferguson M, Heath A. Report of a collaborative study to calibrate the second international standard for parvovirus B19 antibody. Biologicals 2004; 32: 207-212.
18. Thierfelder W, et al. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey. European Journal of Epidemiology 1998; 17: 429-435.
19. Hellenbrand W, et al. Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997-1998. European Journal of Clinical Microbiology and Infectious Diseases 2005; 24: 131-135.
20. Jöckel KH, et al. Empfehlungen der Arbeitsgruppe 'Epidemiologische Methoden' in der Deutschen Arbeitsgemeinschaft Epidemiologie der Gesellschaft für medizinische Informatik, Biometrie und Epidemiologie (GMDS) und der Deutschen Gesellschaft für Sozialmedizin und Prävention (DGSMP) zur Messung und Quantifizierung soziodemographischer Merkmale in der epidemiologischen Studien. In: Ahrens W, Bellach BM, Jöckel KH, eds. Messung soziodemographischer Merkmale in der Epidemiologie. RKI Schriften 1/98 MMV Medizin Verlag (Munich), 1998, pp. 23-49.
21. Letaief M, et al. Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: Differential implications for prevention of transfusional transmission. Transfusion Science 1997; 18: 523-530.
22. Manaresi E, et al. Seroprevalence of IgG against conformational and linear capsid antigens of parvovirus B19 in Italian blood donors. Epidemiology and Infection 2004; 132: 857-862.
23. Public Health Laboratory Service Working Party on Fifth Disease. Prospective study of human parvovirus (B19) infection in pregnancy. British Medical Journal 1990; 300: 413-420.
24. Gratacos E, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. Journal of Infectious Diseases 1995; 171: 1360-1363.
25. Harger JH, et al. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: Risks and symptoms. Obstetrics and Gynecology 1998; 91: 413-420.
26. Rodis JF, et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: A survey of members of the Society of Perinatal Obstetricians. American Journal of Obstetrics and Gynecology 1998; 179: 985-988.
27. Valeur-Jensen AK, et al. Risk factors for parvovirus B19 infection in pregnancy. Journal of the American Medical Association 1999; 281: 1099-1105.
28. Jensen IP, et al. An epidemic of parvovirus B19 in a population of 3,596 pregnant women: A study of sociodemographic and medical risk factors. British Journal of Obstetrics and Gynaecology 2000; 107: 637-643.
29. Alanen A, et al. Seroprevalence, incidence of prenatal infections and reliability of maternal history of varicella zoster virus, cytomegalovirus, herpes simplex virus and parvovirus B19 infection in South-Western Finland. British Journal of Obstetrics and Gynaecology 2005; 112: 50-56.
30. Van Gessel PH, et al. Incidence of parvovirus B19 infection among an unselected population of pregnant women in the Netherlands: A prospective study. European Journal of Obstetrics & Gynecology and Reproductive Biology 2006; 128: 46-49.
31. Odland JO, et al. Seropositivity of cytomegalovirus, parvovirus and rubella in pregnant women and recurrent aborters in Leningrad County, Russia. Acta Obstetrica Gynecologica Scandinavica 2001; 80: 1025-1029.
32. Skjöldebrand-Sparre L, et al. A prospective study of antibodies against parvovirus B19 in pregnancy. Acta Obstetrica Gynecologica Scandinavica 1996; 75: 336-339.
33. Gilbert NL, et al. Seroprevalence of parvovirus B19 infection in daycare educators. Epidemiology and Infection 2005; 133: 299-304.
34. Chisaka H, et al. Clinical manifestations and outcomes of parvovirus B19 infection during pregnancy in Japan. Tohoku Journal of Experimental Medicine 2006; 209: 277-283.